CA3041434A1 - Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications - Google Patents
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications Download PDFInfo
- Publication number
- CA3041434A1 CA3041434A1 CA3041434A CA3041434A CA3041434A1 CA 3041434 A1 CA3041434 A1 CA 3041434A1 CA 3041434 A CA3041434 A CA 3041434A CA 3041434 A CA3041434 A CA 3041434A CA 3041434 A1 CA3041434 A1 CA 3041434A1
- Authority
- CA
- Canada
- Prior art keywords
- acid sequence
- dose
- amino acid
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 141
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 101710104976 Interferon gamma-related Proteins 0.000 title description 2
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 358
- 238000011282 treatment Methods 0.000 claims description 284
- 150000001413 amino acids Chemical group 0.000 claims description 195
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 125
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 79
- 239000003795 chemical substances by application Substances 0.000 claims description 75
- 230000037396 body weight Effects 0.000 claims description 67
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 62
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 58
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 57
- 108010074328 Interferon-gamma Proteins 0.000 claims description 47
- 239000000243 solution Substances 0.000 claims description 47
- 229960003130 interferon gamma Drugs 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 29
- 230000003442 weekly effect Effects 0.000 claims description 28
- 206010052779 Transplant rejections Diseases 0.000 claims description 27
- 229960003957 dexamethasone Drugs 0.000 claims description 27
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 27
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 26
- 102000008070 Interferon-gamma Human genes 0.000 claims description 24
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 18
- 230000001064 anti-interferon Effects 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- QAWLKTDBUQOFEF-UHFFFAOYSA-N 3-(4-bromophenyl)propanenitrile Chemical compound BrC1=CC=C(CCC#N)C=C1 QAWLKTDBUQOFEF-UHFFFAOYSA-N 0.000 claims description 13
- 229960002885 histidine Drugs 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 150000004682 monohydrates Chemical class 0.000 claims description 13
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229940068968 polysorbate 80 Drugs 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 210000001185 bone marrow Anatomy 0.000 claims description 11
- 208000024908 graft versus host disease Diseases 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 11
- 208000014673 secondary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 11
- 239000003018 immunosuppressive agent Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 9
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 8
- 238000009097 single-agent therapy Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 208000026326 Adult-onset Still disease Diseases 0.000 claims description 6
- 208000031287 Primary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 6
- 238000011262 co‐therapy Methods 0.000 claims description 6
- 208000014681 genetic hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 6
- 206010061192 Haemorrhagic fever Diseases 0.000 claims description 5
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 201000000306 sarcoidosis Diseases 0.000 claims description 5
- 238000002659 cell therapy Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 abstract description 35
- 238000001802 infusion Methods 0.000 description 451
- 238000001990 intravenous administration Methods 0.000 description 296
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 295
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 129
- 108010014231 Chemokine CXCL9 Proteins 0.000 description 129
- 201000010099 disease Diseases 0.000 description 89
- 102000019034 Chemokines Human genes 0.000 description 54
- 108010012236 Chemokines Proteins 0.000 description 54
- 210000002966 serum Anatomy 0.000 description 45
- 230000001225 therapeutic effect Effects 0.000 description 45
- 230000004044 response Effects 0.000 description 43
- 239000012634 fragment Substances 0.000 description 40
- 230000001965 increasing effect Effects 0.000 description 40
- 108090001005 Interleukin-6 Proteins 0.000 description 39
- 102000004889 Interleukin-6 Human genes 0.000 description 39
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 39
- 229940100601 interleukin-6 Drugs 0.000 description 39
- 230000009885 systemic effect Effects 0.000 description 39
- 239000000090 biomarker Substances 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 35
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 35
- 238000012423 maintenance Methods 0.000 description 35
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 34
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 34
- 208000003456 Juvenile Arthritis Diseases 0.000 description 34
- 210000001772 blood platelet Anatomy 0.000 description 34
- 208000015181 infectious disease Diseases 0.000 description 34
- 150000007523 nucleic acids Chemical group 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 238000005070 sampling Methods 0.000 description 33
- 102000008857 Ferritin Human genes 0.000 description 31
- 108050000784 Ferritin Proteins 0.000 description 31
- 238000008416 Ferritin Methods 0.000 description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 230000006872 improvement Effects 0.000 description 28
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 27
- 108010036949 Cyclosporine Proteins 0.000 description 27
- 239000003862 glucocorticoid Substances 0.000 description 27
- 230000006698 induction Effects 0.000 description 27
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 25
- 229930105110 Cyclosporin A Natural products 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 25
- 108090000695 Cytokines Proteins 0.000 description 25
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 25
- 238000006386 neutralization reaction Methods 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 102100037850 Interferon gamma Human genes 0.000 description 23
- 230000005856 abnormality Effects 0.000 description 23
- 206010003246 arthritis Diseases 0.000 description 23
- 230000002596 correlated effect Effects 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 229940037128 systemic glucocorticoids Drugs 0.000 description 22
- 108010008980 Chemokine CXCL11 Proteins 0.000 description 21
- 102000006577 Chemokine CXCL11 Human genes 0.000 description 21
- 102000004503 Perforin Human genes 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 21
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 20
- 210000000440 neutrophil Anatomy 0.000 description 20
- 229930192851 perforin Natural products 0.000 description 20
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 19
- 108010082126 Alanine transaminase Proteins 0.000 description 19
- 239000012620 biological material Substances 0.000 description 19
- 210000003169 central nervous system Anatomy 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 19
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 18
- 229960005420 etoposide Drugs 0.000 description 18
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 17
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 17
- 208000025747 Rheumatic disease Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 15
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 15
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 15
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 15
- 108010056995 Perforin Proteins 0.000 description 14
- 238000010171 animal model Methods 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 14
- 230000000977 initiatory effect Effects 0.000 description 14
- 230000008506 pathogenesis Effects 0.000 description 14
- 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 206010033661 Pancytopenia Diseases 0.000 description 12
- 241000219061 Rheum Species 0.000 description 12
- 230000002159 abnormal effect Effects 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 206010050685 Cytokine storm Diseases 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 11
- 206010052015 cytokine release syndrome Diseases 0.000 description 11
- 208000024389 cytopenia Diseases 0.000 description 11
- 230000009266 disease activity Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 108010033990 rab27 GTP-Binding Proteins Proteins 0.000 description 10
- 102000006581 rab27 GTP-Binding Proteins Human genes 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000000589 Interleukin-1 Human genes 0.000 description 9
- 108010002352 Interleukin-1 Proteins 0.000 description 9
- 206010041660 Splenomegaly Diseases 0.000 description 9
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 9
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 9
- 206010060872 Transplant failure Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 229940012952 fibrinogen Drugs 0.000 description 9
- 208000027866 inflammatory disease Diseases 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108010049003 Fibrinogen Proteins 0.000 description 8
- 102000008946 Fibrinogen Human genes 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 102000003810 Interleukin-18 Human genes 0.000 description 8
- 108090000171 Interleukin-18 Proteins 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 102000002689 Toll-like receptor Human genes 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 102100040328 Zinc finger and BTB domain-containing protein 12 Human genes 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 6
- 208000034486 Multi-organ failure Diseases 0.000 description 6
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229960001265 ciclosporin Drugs 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000007420 reactivation Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108700012920 TNF Proteins 0.000 description 5
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 208000015294 blood coagulation disease Diseases 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- -1 coatings Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008093 supporting effect Effects 0.000 description 5
- 230000003319 supportive effect Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000004653 Griscelli syndrome type 2 Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 101001054329 Homo sapiens Interferon epsilon Proteins 0.000 description 4
- 101000644045 Homo sapiens Protein unc-13 homolog D Proteins 0.000 description 4
- 208000028958 Hyperferritinemia Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100026688 Interferon epsilon Human genes 0.000 description 4
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 239000010836 blood and blood product Substances 0.000 description 4
- 229940125691 blood product Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000009395 genetic defect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011419 induction treatment Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229960004584 methylprednisolone Drugs 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001179 synovial fluid Anatomy 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000011357 CAR T-cell therapy Methods 0.000 description 3
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 3
- 239000003154 D dimer Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000706156 Homo sapiens Syntaxin-11 Proteins 0.000 description 3
- 101000820478 Homo sapiens Syntaxin-binding protein 2 Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 208000004554 Leishmaniasis Diseases 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- 206010035551 Pleocytosis Diseases 0.000 description 3
- 102100020988 Protein unc-13 homolog D Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100031115 Syntaxin-11 Human genes 0.000 description 3
- 102100021680 Syntaxin-binding protein 2 Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940125385 biologic drug Drugs 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960001838 canakinumab Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 108010052295 fibrin fragment D Proteins 0.000 description 3
- 238000011990 functional testing Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 206010024378 leukocytosis Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229960003989 tocilizumab Drugs 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000028973 vesicle-mediated transport Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 206010051226 Campylobacter infection Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108010002947 Connectin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 201000002563 Histoplasmosis Diseases 0.000 description 2
- 101001005139 Homo sapiens Protein limb expression 1 homolog Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000005353 IP-10 production Effects 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 206010065048 Latent tuberculosis Diseases 0.000 description 2
- 206010057168 Leishmania infections Diseases 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000142787 Pneumocystis jirovecii Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 206010040550 Shigella infections Diseases 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100026260 Titin Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Chemical group 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960004238 anakinra Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000029944 familial hemophagocytic lymphohistiocytosis type 1 Diseases 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 210000003701 histiocyte Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 231100000683 possible toxicity Toxicity 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 231100001251 short-term toxicity Toxicity 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LXOFYPKXCSULTL-UHFFFAOYSA-N 2,4,7,9-tetramethyldec-5-yne-4,7-diol Chemical compound CC(C)CC(C)(O)C#CC(C)(O)CC(C)C LXOFYPKXCSULTL-UHFFFAOYSA-N 0.000 description 1
- 206010066817 Activation syndrome Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100446725 Caenorhabditis elegans flh-1 gene Proteins 0.000 description 1
- 101100446726 Caenorhabditis elegans flh-2 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000016937 Chemokine CXCL9 Human genes 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000014669 Hemophagocytic syndrome associated with an infection Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 102100030231 Homeobox protein cut-like 2 Human genes 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000804865 Homo sapiens E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000726714 Homo sapiens Homeobox protein cut-like 2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010068237 Hypertransaminasaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021460 Immunodeficiency syndromes Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 108010001212 Munc18 Proteins Proteins 0.000 description 1
- 102000002069 Munc18 Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100222378 Mus musculus Cxcl10 gene Proteins 0.000 description 1
- 101100441533 Mus musculus Cxcl9 gene Proteins 0.000 description 1
- 101100339600 Mus musculus Hprt1 gene Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 101150034595 NLRC4 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710141059 Protein unc-13 homolog D Proteins 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 101000726742 Rattus norvegicus Homeobox protein cut-like 1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000050707 Syntaxin-11 Human genes 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000029625 X-linked lymphoproliferative disease due to SH2D1A deficiency Diseases 0.000 description 1
- 208000012453 X-linked lymphoproliferative disease due to XIAP deficiency Diseases 0.000 description 1
- 201000001271 X-linked lymphoproliferative syndrome 1 Diseases 0.000 description 1
- 201000001270 X-linked lymphoproliferative syndrome 2 Diseases 0.000 description 1
- 101150101997 XLP1 gene Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 229940086174 acyclovir 200 mg Drugs 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000000876 binomial test Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011342 chemoimmunotherapy Methods 0.000 description 1
- 230000018096 chemokine (C-X-C motif) ligand 9 production Effects 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229960003950 combination of corticosteroids Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000009433 disease-worsening effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000030279 prolonged fever Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000011215 vesicle docking Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| US62/411,783 | 2016-10-24 | ||
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3041434A1 true CA3041434A1 (en) | 2018-05-03 |
Family
ID=60957345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041434A Pending CA3041434A1 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (ko) |
| JP (2) | JP2019532970A (ko) |
| KR (1) | KR20190071785A (ko) |
| CN (1) | CN110167593A (ko) |
| AU (1) | AU2017352033A1 (ko) |
| BR (1) | BR112019008156A2 (ko) |
| CA (1) | CA3041434A1 (ko) |
| EA (1) | EA201990930A1 (ko) |
| IL (1) | IL266174B2 (ko) |
| MX (1) | MX2019004766A (ko) |
| SG (1) | SG11201903659WA (ko) |
| WO (1) | WO2018078442A2 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118165113A (zh) * | 2016-04-26 | 2024-06-11 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU764211C (en) * | 1998-12-01 | 2006-03-30 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| MX2007008719A (es) | 2005-01-27 | 2007-09-11 | Novimmune Sa | Anticuerpos anti-interferon gamma y metodos de uso de los mismos. |
| CN101896163A (zh) * | 2007-12-21 | 2010-11-24 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| EP2791168A1 (en) * | 2011-11-23 | 2014-10-22 | Amgen Inc. | Methods of treatment using an antibody against interferon gamma |
| KR20170018810A (ko) * | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| MX2017014294A (es) * | 2015-05-07 | 2018-08-09 | Novimmune Sa | Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. |
-
2017
- 2017-10-24 BR BR112019008156A patent/BR112019008156A2/pt unknown
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active IP Right Cessation
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en active Pending
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en active Application Filing
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL266174A (en) | 2019-06-30 |
| EA201990930A1 (ru) | 2019-11-29 |
| WO2018078442A3 (en) | 2018-08-23 |
| WO2018078442A2 (en) | 2018-05-03 |
| JP7562074B2 (ja) | 2024-10-07 |
| MX2019004766A (es) | 2019-09-27 |
| AU2017352033A1 (en) | 2019-06-06 |
| IL266174B1 (en) | 2024-06-01 |
| SG11201903659WA (en) | 2019-05-30 |
| JP2019532970A (ja) | 2019-11-14 |
| KR20190071785A (ko) | 2019-06-24 |
| EP3528845A2 (en) | 2019-08-28 |
| CN110167593A (zh) | 2019-08-23 |
| IL266174B2 (en) | 2024-10-01 |
| BR112019008156A2 (pt) | 2019-07-02 |
| JP2022187025A (ja) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11236158B2 (en) | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications | |
| US20210101972A1 (en) | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers | |
| Gauckler et al. | Rituximab in adult minimal change disease and focal segmental glomerulosclerosis-What is known and what is still unknown? | |
| JP7562074B2 (ja) | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン | |
| Gerfaud-Valentin et al. | Adult-onset Still's disease | |
| CA3116725A1 (en) | Secukinumab for use in the treatment of psoriatic arthritis | |
| AU2014228553A1 (en) | Methods for treating Crohn's disease using an anti-IL23 antibody | |
| US20140314746A1 (en) | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma | |
| EA042261B1 (ru) | Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний | |
| US20220010007A1 (en) | Treatment for Giant Cell Arteritis | |
| US20220267428A1 (en) | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS | |
| KR20240148970A (ko) | 인터페론 감마 관련 적응증의 치료 또는 예방을 위한 방법, 조성물 및 투여 요법 | |
| Pile et al. | Disease-modifying anti-rheumatic drugs | |
| Byng-Maddick | Differential effects of anti-TNF therapies for inflammatory arthritides on immune responses to Mycobacterium tuberculosis | |
| WO2020096664A1 (en) | Treatment for giant cell arteritis | |
| Lübbers | Profiling Seropositive Arthralgia Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| EEER | Examination request |
Effective date: 20220928 |
|
| EEER | Examination request |
Effective date: 20220928 |